- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 5 | SEC Filings | ||
| 02.04. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| GALERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.02. | Galera Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.12.24 | Galera Therapeutics completes acquisition of Nova Pharmaceuticals | 434 | GlobeNewswire (Europe) | Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer. Lead program is Phase... ► Artikel lesen | |
| 04.09.24 | Delisting of Securities of Liberty Resources Acquisition Corp.; Achari Ventures Holdings Corp. I; PetVivo Holdings, Inc.; Galera Therapeutics, Inc.; Clean Energy Special Situations Corp.; Capitalworks Emerging Markets Acquisition ... | 180 | GlobeNewswire (Europe) | NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of Liberty Resources Acquisition Corp. Liberty Resources... ► Artikel lesen | |
| 14.08.24 | Galera Therapeutics: Galera Announces Board Approval of Complete Liquidation and Dissolution | 220 | GlobeNewswire (Europe) | MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,230 | -16,44 % | Evotec-Aktie mit Kursgewinnen (7,346 €) | Im Plus liegt derzeit der Anteilsschein von Evotec . Das Papier kostete zuletzt 7,35 Euro. Heute hat sich am deutschen Aktienmarkt das Wertpapier von Evotec zwischenzeitlich um 3,41 Prozent verteuert.... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 56,00 | 0,00 % | CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading | ||
| MAINZ BIOMED | 1,960 | -7,11 % | EQS-News: Mainz BioMed N.V.: Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest der nächsten Generation und Portfolio-Erweiterung durch Erwerb im Bereich Pankreaskrebs | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Sonstiges
Mainz Biomeds Update für das erste Halbjahr 2025: Beschleunigung des Wegs zur FDA-Zulassung für Darmkrebstest... ► Artikel lesen | |
| TREVENA | 0,153 | 0,00 % | Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc. ... | NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the Class A Ordinary Shares, unit, and warrant of Patria Latin American Opportunity Acquisition... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,350 | +1,90 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
| GALAPAGOS NV | 27,820 | +1,31 % | Galapagos NV: Galapagos Appoints Aaron Cox as Chief Financial Officer | Former Horizon CFO joins Galapagos with deep expertise in international corporate finance, M&A, business development and strategic leadership
Mechelen, Belgium; June 23, 2025, 07:30 CET; regulated... ► Artikel lesen | |
| CENTOGENE | 0,110 | +4,76 % | Research and Markets: Europe Hereditary Genetic Testing Market Research 2024-2033, Competitive Analysis of Centogene, Eurofins Scientific, and F. Hoffmann-La Roche - ResearchAndMarkets.com | The "Europe Hereditary Genetic Testing Market: Focus on Genetic Testing Type and Country Analysis and Forecast, 2024-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 3,180 | -4,65 % | Cardiff Oncology vor Entscheidung: Die spannendste Krebs-Aktie! | Es ist der gewohnte Raketenstart nach Maß: Unser neuer Community-Tipp Cardiff Oncology legt furios los, gewinnt allein seit unserer Enthüllung im Live Chat vor genau einer Woche über 20% an Wert. Und... ► Artikel lesen | |
| NOVOCURE | 13,750 | -0,22 % | Novocure to Report Second Quarter 2025 Financial Results | Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.
Novocure management will host a conference call and webcast... ► Artikel lesen | |
| SENSEI BIOTHERAPEUTICS | 2,813 | -100,00 % | XFRA FA20,0RA0,4070: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFORWARD AIR CORP.... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,018 | -0,69 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma | SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the... ► Artikel lesen | |
| AC IMMUNE | 1,838 | +2,57 % | AC Immune SA: AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update | AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative diseasesPositive... ► Artikel lesen | |
| CYTOKINETICS | 31,600 | -0,63 % | Cytokinetics, Incorporated: Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,020 | +1,61 % | Sports Injuries Made Every Day a Mortal Struggle Until The Spero Clinic Began Treatment: Kole Jackson's Story | FAYETTEVILLE, ARKANSAS / ACCESS Newswire / July 7, 2025 / With around 30 million children participating in organized sports in the U.S., almost all of them will experience some kind of injury while... ► Artikel lesen | |
| EIGER BIOPHARMACEUTICALS | 5,840 | -100,00 % | China Market Update: US-China Trade Negotiators Climb Switzerland's Face Of The Eiger, Week In Review |
GALERA THERAPEUTICS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GALERA THERAPEUTICS INC finden Sie auf Wallstreet Online.